Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00410306
Registration number
NCT00410306
Ethics application status
Date submitted
11/12/2006
Date registered
12/12/2006
Date last updated
24/09/2010
Titles & IDs
Public title
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
Query!
Scientific title
International, Multi-center Post Authorization Surveillance Study on the Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido)
Query!
Secondary ID [1]
0
0
2005/00888
Query!
Secondary ID [2]
0
0
14203
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IPASS Nebido
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Male
0
0
Query!
Hypogonadism
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Testosterone Undecanoate (Nebido, BAY86-5037)
Group 1 -
Treatment: Drugs: Testosterone Undecanoate (Nebido, BAY86-5037)
Patients from routine practice
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverse events, adverse drug reactions, patient reported tolerability
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
during 4 injection intervals
Query!
Secondary outcome [1]
0
0
Change in laboratory values (total testosterone, estradiol, SHGB, FSH, LH) from baseline to end of observation
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
after 4 injection intervals
Query!
Secondary outcome [2]
0
0
Change in subjective assessment of the patient (overall sexual desire/libido, vigor/vitality, mood, ability to concentrate) from baseline to end of observation
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
after 4 injection intervals
Query!
Secondary outcome [3]
0
0
Change in intensity of symptoms or disorders associated with low testosterone (hot flushes or excessive sweating, sleep disturbances, decreased physical strength and erectile dysfunction) from baseline to end of observation
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
after 4 injection intervals
Query!
Secondary outcome [4]
0
0
Patient reported outcome at end of observation (satisfaction with current androgen therapy, comparison to previous androgen therapy, if applicable)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
after 4 injection intervals
Query!
Secondary outcome [5]
0
0
Treatment continuation rate
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
after 4 injection intervals
Query!
Secondary outcome [6]
0
0
Vital signs and anthropometric measurements (Blood pressure, heart rate, weight and waist circumference)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
during 4 injection intervals
Query!
Secondary outcome [7]
0
0
Laboratory values (PSA, hemoglobin, hematocrit, HbA1C, T-chol, HDL-chol, LDL-chol, triglycerides)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
during 4 injection intervals
Query!
Secondary outcome [8]
0
0
Digital rectal examination
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
during 4 injection intervals
Query!
Eligibility
Key inclusion criteria
- Male hypogonadal patients eligible for long-term testosterone therapy who have newly
been prescribed Nebido® in accordance with the terms of the marketing authorization
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients presenting with contraindications as stated in the product information
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1493
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Many Locations
Query!
Recruitment postcode(s) [1]
0
0
- Many Locations
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Many Locations
Query!
Country [2]
0
0
Bulgaria
Query!
State/province [2]
0
0
Many Locations
Query!
Country [3]
0
0
Colombia
Query!
State/province [3]
0
0
Many Locations
Query!
Country [4]
0
0
Czech Republic
Query!
State/province [4]
0
0
Many Locations
Query!
Country [5]
0
0
Estonia
Query!
State/province [5]
0
0
Many Locations
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Many Locations
Query!
Country [7]
0
0
Hong Kong
Query!
State/province [7]
0
0
Many Locations
Query!
Country [8]
0
0
Indonesia
Query!
State/province [8]
0
0
Many Locations
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Many Locations
Query!
Country [10]
0
0
Jordan
Query!
State/province [10]
0
0
Many Locations
Query!
Country [11]
0
0
Kazakhstan
Query!
State/province [11]
0
0
Many Locations
Query!
Country [12]
0
0
Korea, Republic of
Query!
State/province [12]
0
0
Many Locations
Query!
Country [13]
0
0
Latvia
Query!
State/province [13]
0
0
Many Locations
Query!
Country [14]
0
0
Lebanon
Query!
State/province [14]
0
0
Many Locations
Query!
Country [15]
0
0
Lithuania
Query!
State/province [15]
0
0
Many Locations
Query!
Country [16]
0
0
Macedonia, The Former Yugoslav Republic of
Query!
State/province [16]
0
0
Many Locations
Query!
Country [17]
0
0
Malaysia
Query!
State/province [17]
0
0
Many Locations
Query!
Country [18]
0
0
Malta
Query!
State/province [18]
0
0
Many Locations
Query!
Country [19]
0
0
Mexico
Query!
State/province [19]
0
0
Many Locations
Query!
Country [20]
0
0
Moldova, Republic of
Query!
State/province [20]
0
0
Many Locations
Query!
Country [21]
0
0
Philippines
Query!
State/province [21]
0
0
Many Locations
Query!
Country [22]
0
0
Romania
Query!
State/province [22]
0
0
Many Locations
Query!
Country [23]
0
0
Russian Federation
Query!
State/province [23]
0
0
Many Locations
Query!
Country [24]
0
0
Saudi Arabia
Query!
State/province [24]
0
0
Many Locations
Query!
Country [25]
0
0
Singapore
Query!
State/province [25]
0
0
Many Locations
Query!
Country [26]
0
0
Slovenia
Query!
State/province [26]
0
0
Many Locations
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Many Locations
Query!
Country [28]
0
0
Taiwan
Query!
State/province [28]
0
0
Many Locations
Query!
Country [29]
0
0
Thailand
Query!
State/province [29]
0
0
Many Locations
Query!
Country [30]
0
0
Turkey
Query!
State/province [30]
0
0
Many Locations
Query!
Country [31]
0
0
Ukraine
Query!
State/province [31]
0
0
Many Locations
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Many Locations
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an observational study with a drug called Nebido, a new testosterone replacement
therapy, which is available for the treatment of male hypogonadism. The benefit and safety of
Nebido have already been thoroughly evaluated through well controlled clinical trials. The
main purpose of this observational study is to confirm the established safety profile of
Nebido in daily clinical practice.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00410306
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00410306
Download to PDF